To determine the prevalence of immunocytochemical positivities for a panel of antibodies in benign and malignant cells in effusions with known follow-up in order to use these as diagnostic markers. Besides their ability to identify malignant epithelial cells their contribution to the differential diagnosis between @entity189 and @entity2615 was investigated. 101 @entity5 cell positive and 53 negative effusions were stained with 12 different antibodies. Results were scored semiquantitatively per cell type. Furthermore, DNA-image cytometry was performed. While prevalence of Ber- @entity2912 positivity was 95.4% in @entity189 cells, it was 0% in those from @entity2615 . No cell type reacted with this marker in benign effusions (0%). Ber- @entity2912 correctly differentiated between @entity189 and @entity2615 in 98.0%. Prevalence of DNA-aneuploidy was 95.4% in metastatic @entity189 , 57.1% in @entity2615 and 0% in reactive effusions. Combining immunocytochemistry (Ber- @entity2912 positivity) and DNA-image cytometry (aneuploidy) results in a 100% detection of metastatic @entity189 and 57.1% of @entity2615 . Both markers furthermore allowed a correct differentiation of these entities in 98%.

Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology I. Prevalence of markers in XXXX cell positive and negative smears.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity2912 :: ('5734', 'Gene') :: ['EP4'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomatoses', 'carcinomas', 'metastatic carcinoma'] @entity2615 :: ('MESH:D008654', 'Disease') :: ['mesotheliomas', 'mesothelioma']
@entity5 :: (MESH:D009369,Disease) :: ['tumour']
